Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products CHMP/437/04 Rev 1. 2015. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 29 July 2019.
Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for Industry. 2015. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 29 July 2019.
Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010. 2012. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Accessed 29 July 2019.
De Mora F. Biosimilar: what it is not. Br J Clin Pharmacol. 2015;80:949–56.
Prasad V. Non-inferiority trials in medicine: practice changing or a self-fulfilling prophecy? J Gen Intern Med. 2018;33:3–5.
Stewart A, Aubrey P, Belsey J. Addressing the health technology assessment of biosimilar pharmaceuticals. Curr Med Res Opin. 2010;26:2119–26.
Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3. https://doi.org/10.7249/PE264.
Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–20.
Food and Drug Administration. Addendum to primary clinical review. Recommendation on regulatory action. Inflectra. 2016. Available at: https://www.fda.gov/media/99018/download. Accessed 29 July 2019.
Committee for Medicinal Products for Human Use (CHMP). Assessment report. Inflectra. EMA/CHMP/589422/2013. 2013. Available at: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Accessed 29 July 2019.
Committee for Medicinal Products for Human Use (CHMP). Guideline on the development of new medicinal products for the treatment of Crohn’s disease. CPMP/EWP/2284/99 Rev. 2. 2016. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-new-medicinal-products-treatment-crohns-disease-revision-2_en.pdf. Accessed 29 July 2019.
Ben-Horin S, Heap GA, Ahmad T, et al. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Expert Rev Gastroenterol Hepatol. 2015;9:27–34.
Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14:1685–96.
Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42:177–83.
Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9–17.
Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18:S68–80.
Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509–20.
Roda G, Jharap B, Neeraj N, Colombel J-F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–24.
Gomollón F, Dignass A, Annese V 3rd, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease: 2016. Part 1: diagnosis and medical management. J Crohns Colitis. 2016;2017(11):3–25.
Medicines.org.uk. Remicade 100 mg powder for concentrate for solution for infusion: summary of product characteristics (SPC). eMC 1–16 (2009). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf. Accessed 25 Jun 2018.
Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459–63.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.
Office for National Statistics. UK life tables 2012–2014. 2016. Available at: https://www.gov.uk/government/statistics/national-life-tables-2012-to-2014. Accessed 29 July 2019.
Lee LYW, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:1078–85.
Miheller P, Lakatos PL, Horváth G, et al. Efficacy and safety of infliximab induction therapy in Crohn’s Disease in Central Europe: a Hungarian nationwide observational study. BMC Gastroenterol. 2009;9:66.
Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–7.
Saito S, Shimizu U, Nan Z, et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn’s disease: a cost-effectiveness analysis. J Crohns Colitis. 2013;7:167–74.
Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49–57.
O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1–6.
Siegel CA, Finlayson SRG, Sands BE, Tosteson ANA. Adverse events do not outweigh benefits of combination therapy for crohn’s disease in a decision analytic model. Clin Gastroenterol Hepatol. 2012;10:46–51.
Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR. Strategies for the prevention of postoperative recurrence in Crohn’s disease: results of a decision analysis. Am J Gastroenterol. 2011;106:2009–17.
Gregor JC, McDonald JWD, Klar N, Wall R, Atkinson K, Lamba B, et al. An evaluation of utility measurement in Crohn’s disease. Inflamm Bowel Dis. 1997;3:265–76.
Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease. Inflamm Bowel Dis. 2012;18:1608–16.
Curtis L. PSSR unit costs of health and social care 2013. 2013. Available at: https://www.pssru.ac.uk/pub/uc/uc2013/full-with-covers.pdf. Accessed 29 July 2019.
Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab: a critical care perspective. Crit Care. 2012;16:231.
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265–74.
National Institute for Health and Care Excellence. Infliximab and adalimumab for the treatment of Crohn’s disease—TA187. 2010. p. 1–44. Available at: https://www.nice.org.uk/guidance/ta187/resources/infliximab-and-adalimumab-for-the-treatment-of-crohns-disease-pdf-82598501180869. Accessed 29 July 2019.
National Institute for Health and Care Excellence. Ustekinumab for treating moderately to severely active Crohn’s disease after previous treatment—Technology appraisal guidance TA456. 2017. Available at: https://www.nice.org.uk/guidance/ta456. Accessed 29 July 2019.
National Institute for Health and Care Excellence. Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy: technology appraisal guidance TA352. 2015. https://doi.org/https://nice.org.uk/guidance/ta352. Accessed 1 Jul 2018.
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. Available at: https://www.nice.org.uk/guidance/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 29 July 2019.
medicines.org.uk. Humira 40 mg solution for injection in pre-filled syringe: summary of product characteristics (SPC). eMC (2003). https://www.medicines.org.uk/emc/product/2150/smpc#CLINICAL_PARTS. Accessed 10 Jul 2018.
medicines.org.uk. STELLARA 90 mg solution for injections: summary of product characteristics (SPC). eMC (2009). https://www.medicines.org.uk/emc/product/4413/smpc. Accessed 10 Jul 2018.
medicines.org.uk. Entyvio 300 mg powder for concentrate for solution for infusion: summary of product characteristics (SPC). eMC (2014). https://www.medicines.org.uk/emc/product/5442/smpc. Accessed 10 Jul 2018.
Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:1984–9.
Da W, Zhu J, Wang L, Lu Y. Adalimumab for Crohn’s disease after infliximab treatment failure. Eur J Gastroenterol Hepatol. 2013;25:885–91.
Colombel J-F, Sloan S, Gasink C, et al. A147 response and remission after 16 weeks of ustekinumab: an all patients analysis from the UNITI Crohn’s studies. J Can Assoc Gastroenterol. 2018;1(Suppl. 2):219–20.
Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.
Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(618–27):e3.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.
Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample. Med Decis Making. 2014;34:311–26.
National Institute for Health and Care Excellence. Infliximab and adalimumab for the treatment of Crohn’s disease costing template and report: technology appraisal guidance 187. 2010. Available at: https://www.nice.org.uk/guidance/ta187. Accessed 29 July 2019.
Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS): explanation and elaboration. A report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. Value Health. 2013;16:231–50.
Lynd LD, O’Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol. 2004;57:795–803.
Breeze P, Brennan A. Valuing trial designs from a pharmaceutical perspective using value-based pricing. Health Econ. 2014;18:S37–54.
Kim YH, Ye BD, Pesegova M, et al. DOP061 phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: early efficacy and safety results. J Crohns Colitis. 2017;11:S62.
Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO Cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23:233–43.
Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65:1132–8.
Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699–707.
Acha V, Mestre-Ferrandiz J. Translating European regulatory approval into healthcare uptake for biosimilars: the second translational gap. Technol Anal Strateg Manag. 2017;29:263–75. https://doi.org/10.1080/09537325.2017.1285396.
National Institute for Health and Care Excellence. NICE’s biosimilar
position statement. 2014; 7–8.
Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–64.
Kennedy NA, Heap GA, Green HD, UK Inflammatory Bowel Disease Pharmacogenetics Study Group, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–53.